| Target Validation Information | |||||
|---|---|---|---|---|---|
| Target ID | T58921 | ||||
| Target Name | Peroxisome proliferator activated receptor gamma | ||||
| Target Type | Successful |
||||
| Drug Potency against Target | Netoglitazone | Drug Info | EC50 = 100 nM | [552339] | |
| Rosiglitazone + simvastatin | Drug Info | IC50 = 23 nM | [552531] | ||
| Rosiglitazone XR | Drug Info | EC50 = 40 nM | [552515] | ||
| Rosiglitazone + metformin | Drug Info | EC50 = 200 nM | [553285] | ||
| Pioglitazone | Drug Info | EC50 = 580 nM | [552515] | ||
| TESAGLITAZAR | Drug Info | Ki = 200 nM | [527158] | ||
| References | |||||
| Ref 552339 | Treatment of non-insulin-dependent diabetes mellitus. Expert Opin Investig Drugs. 2003 Apr;12(4):623-33. | ||||
| Ref 552531 | Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr Opin Pharmacol. 2005 Aug;5(4):366-73. | ||||
| Ref 552515 | Nuclear receptors as potential targets for modulating reverse cholesterol transport. Curr Top Med Chem. 2005;5(3):265-82. | ||||
| Ref 553285 | A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties. J Biol Chem. 1998 Dec 4;273(49):32679-84. | ||||
| Ref 552515 | Nuclear receptors as potential targets for modulating reverse cholesterol transport. Curr Top Med Chem. 2005;5(3):265-82. | ||||
| Ref 527158 | J Med Chem. 2004 Aug 12;47(17):4118-27.Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.